Comparison of the efficacy and safety of hMG and r-FSH+LH preparations with different sources of luteinizing hormone biological activity: a single-center cohort study
DOI:
https://doi.org/10.37800/RM.2.2025.476Keywords:
controlled ovarian stimulation (COS), human menopausal gonadotropin (HMG), follicle-stimulating hormone (FSH), luteinizing hormone (LH), in vitro fertilization (IVF)Abstract
Relevance: Assisted reproductive technologies (ART) play a key role in the treatment of infertility, and one of the important components of controlled ovarian stimulation (COS) protocols is adequate hormonal support, including follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Both human menopausal gonadotropin (HMG), which contains LH activity, and recombinant drugs, such as r-FSH+LH combinations, are used in clinical practice. However, differences in the sources of LH activity may affect both the pharmacodynamics and the clinical efficacy and safety of these drugs.
The study aimed to compare the effectiveness of FSH- and LH-containing drugs in relation to the clinical outcome of controlled ovarian stimulation.
Materials and Methods: A cohort single-center study was conducted from January 2023 to December 2024 at PERSONA International Clinical Center for Reproductive Medicine (Almaty, Kazakhstan). Ninety women with infertility were included in the study and divided into three groups. The clinical outcomes of the groups were compared: the primary endpoints were the total number of retrieved oocytes, the total number of fertilized oocytes, and the number of good-quality blastocysts with Gardner grade ≥3AB.
Results: There was no statistically significant difference in stimulation duration, total dose of exogenous FSH, number of retrieved oocytes, number of normally fertilized oocytes, number of 3-day embryos, average number of blastocysts obtained, and average number of embryos of good morphological quality between the groups.
Conclusions: When choosing a COS scheme, reproductive specialists consider various gonadotropin regimens – FSH-only and HMG-combined. The choice of a particular drug depends on its availability, clinical preferences, ease of use, and cost. Thus, the study confirms that the new HMG drug, which has LH activity due to the added placental human chorionic gonadotropin, is a promising alternative for ovarian stimulation in IVF protocols.
References
Lockwood G, Cometti B, Bogstad J, Erb K, Geyter C, Urbancsek J, Trevisan S, Pocate-Cheriet K, de Ziegler D. A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources. Reprod BioMed Online. 2017;35(1):17-27.
https://www.rbmojournal.com/article/S1472-6483(17)30192-X/fulltext
Orisaka M, Miyazaki Y, Shirafuji A, Tamamura C, Tsuyoshi H, Tsang B, Yoshida Y. The role of pituitary gonadotropins and intraovarian regulators in follicle development: A mini-review. Reprod Med Biol. 2021;20:169-175.
https://doi.org/10.1002/rmb2.12371
Alviggi C, Conforti A, Esteves S, Andersen C, Bosch E, Bühler K, Ferraretti A, Placido G, Mollo A, Fischer R, Humaidan P. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril. 2018;644-664.
https://www.fertstert.org/article/S0015-0282(18)30003-7/fulltext
Рыбина А, Кемел А, Валиев Р, Аскар Е, Танышева Г, Элленбоген А. Современные методы ведения пациенток с бедным овариальным ответом на контролируемую овариальную стимуляцию: обзор литературы. Репродуктивная медицина (Центральная Азия). 2024;4:9-18.
Rybina A.N., Kemel А.B., Valiev R.К., Аskar Y., Tanysheva G.A., A. Ellenbogen. Modern methods of introduction of patients with poor ovarian response to controlled ovarian stimulation: A literature review. Reproductive Medicine (Central Asia). 2024;4:9-18.
https://repromed.kz/index.php/journal/article/view/283
Humaidan P, Schertz J, Fischer R. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology – ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment. BMJ Open. 2015;5(7):e008297.
https://bmjopen.bmj.com/content/5/7/e008297
Casarini L, Riccetti L, Paradiso E, Benevelli R, Lazzaretti C, Sperduti S, Melli B, Tagliavini S, Varani M, Trenti T, Morini D, Falbo A, Villani M, Jonas K, Simoni M. Two human menopausal gonadotrophin (hMG) preparations display different early signaling in vitro. Mol Hum Reprod. 2020;26(12):894-905.
https://doi.org/10.1093/molehr/gaaa070
Capolupo A, Petrocchi S, Melchiorre M, Jonas K, D’Hooghe T, Hanyaloglu A, Sunkara S, Palmese A, Ozgumus B, Amoresano A, Angiuoni G, Montenegro S, Simonе P, Lispi M. Analytical Investigation of the Profile of Human Chorionic Gonadotropin in Highly Purified Human Menopausal Gonadotrophin Preparations. Int J Mol Sci. 2024;25(17):9405.
https://doi.org/10.3390/ijms25179405
Kirshenbaum M, Gil O, Haas J, Nahum R, Zilberberg E, Lebovitz O, Orvieto R. Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome? Reproductive Biology and Endocrinology 2021;19:182
https://doi.org/10.1186/s12958-021-00853-7
Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73(6):1155-1158.
https://www.fertstert.org/article/S0015-0282(00)00518-5
Casarini L, Riccetti L, Pascali F, Nicoli A, Tagliavini S, Trenti T, La Sala GB, Simoni M. Follicle-stimulating hormone potentiates the steroidogenic activity of chorionic gonadotropin and the anti-apoptotic activity of luteinizing hormone in human granulosa-lutein cells in vitro. Mol Cell Endocrinol. 2016;422:103-114.
https://doi.org/10.1016/j.mce.2015.12.008
Farquhar C, Rishworth JR, Brown J, Nelen WLDM, Marjoribanks J. Assisted reproductive technology: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2013;22:(8):CD010537.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Р.К. Валиев, А.Н. Рыбина, А.Б. Кемел, Е. Аскар, Б.Н. Бищекова
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.
